Café des Entrepreneurs le 18 février 2017! - Consulat Général de France à Boston
Craig Cameron Lab on Twitter: "Honored to receive the inaugural @ISARICAR Diversity Speaker Award tonight. https://t.co/GRrmJWCs8P" / Twitter
Idenix Pharmaceuticals: Building a Leading Antiviral Franchise
DEF 14A
Population Pharmacokinetics of Nevirapine, Zidovudine, and Didanosine in Human Immunodeficiency Virus-Infected Patients
thebenefactor
Jean-Pierre Sommadossi - Director at Kezar Life Sciences | The Org
Jean-Pierre Sommadossi - Director at Kezar Life Sciences | The Org
Sommadossi Jean-Pierre Increases Position in Atea Pharmaceuticals (AVIR) | Nasdaq
thebenefactor
BioCentury - Roche in $350M deal with Sommadossi's Atea for what it believes could be first oral COVID-19 antiviral
Medica RCP | HCP
Jean-Pierre Sommadossi - Director at Kezar Life Sciences | The Org
Jean-Pierre Sommadossi's research works | Boston Pharmaceuticals, Cambridge and other places
CORPORATE FACT SHEET
中華民國製藥發展協會
Our Team - Atea Pharmaceuticals
Café des Entrepreneurs le 18 février 2017! - Consulat Général de France à Boston
Phase I dose escalation pharmacokinetics of O-(chloroacetylcarbamoyl) fumagillol (TNP-470) and its metabolites in AIDS patients
CCCC , ASAP Articles, css200810347 | Collection of Czechoslovak Chemical Communications
Jean-Pierre Sommadossi, Atea Pharmaceuticals Inc: Profile and Biography - Bloomberg Markets
![Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-2-modified-n6-substi- Tuted Purine Nucleotides For Hcv Treatment Sommadossi; Jean-Pierre ; et al. [Atea Pharmaceuticals, Inc.]](https://uspto.report/patent/app/20200331956/US20200331956A1-20201022-C00002.png "Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-2-modified-n6-substi- Tuted Purine Nucleotides For Hcv Treatment Sommadossi; Jean-Pierre ; et al. [Atea Pharmaceuticals, Inc.]")
Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-2-modified-n6-substi- Tuted Purine Nucleotides For Hcv Treatment Sommadossi; Jean-Pierre ; et al. [Atea Pharmaceuticals, Inc.]
Jean-Pierre Sommadossi, Ph.D.
![Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-2-modified-n6-substi- Tuted Purine Nucleotides For Hcv Treatment Sommadossi; Jean-Pierre ; et al. [Atea Pharmaceuticals, Inc.]](https://uspto.report/patent/app/20200331956/US20200331956A1-20201022-C00001.png "Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-2-modified-n6-substi- Tuted Purine Nucleotides For Hcv Treatment Sommadossi; Jean-Pierre ; et al. [Atea Pharmaceuticals, Inc.]")
Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-2-modified-n6-substi- Tuted Purine Nucleotides For Hcv Treatment Sommadossi; Jean-Pierre ; et al. [Atea Pharmaceuticals, Inc.]
Jean Sommadossi - Founder & Chief Executive Officer @ Idenix Pharmaceuticals - Crunchbase Person Profile
